Literature DB >> 32165127

Irisin lowers blood pressure by activating the Nrf2 signaling pathway in the hypothalamic paraventricular nucleus of spontaneously hypertensive rats.

Chan-Juan Huo1, Xiao-Jing Yu1, Yao-Jun Sun2, Hong-Bao Li1, Qing Su1, Juan Bai3, Ying Li1, Kai-Li Liu1, Jie Qi1, Shao-Wen Zhou1, Ning Jia4, Guo-Qing Zhu5, Jin-Jun Liu6, Yu-Ming Kang7.   

Abstract

Exercise training is one of the major non-pharmacological treatments for hypertension. However, the central mechanism by which exercise training attenuates the hypertensive responses remains unclear. Irisin is a muscle-secreted cytokine derived from fibronectin type III domain containing 5 (FNDC5) that will be released into the circulation during exercise. We hypothesized that irisin may play a role in the blood pressure regulation by exercise. To examine the hypothesis, our study investigated the effect of irisin on hypertension and its central mechanism. The study was performed in spontaneously hypertensive rats (SHRs) and normotensive Wistar-Kyoto rats. We found that intravenous injection of irisin effectively reduced blood pressure, plasma norepinephrine, paraventricular nucleus (PVN) levels of neuronal activation, oxidative stress and inflammation in SHRs. Moreover, irisin activated nuclear factor E2-related factor-2 (Nrf2) and restored the imbalance of neurotransmitters in the PVN. Our study also found PVN knockdown of Nrf2 abolished the protective effects of irisin on hypertension. These findings demonstrate irisin can improve hypertension via Nrf2-mediated antioxidant in the PVN.
Copyright © 2019. Published by Elsevier Inc.

Entities:  

Keywords:  Hypertension; Irisin; Nrf2; Oxidative stress; Paraventricular nucleus

Year:  2020        PMID: 32165127     DOI: 10.1016/j.taap.2020.114953

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  9 in total

Review 1.  Irisin Regulates Cardiac Responses to Exercise in Health and Diseases: a Narrative Review.

Authors:  Baishu Zhu; Bin Wang; Chen Zhao; Yuanxin Wang; Yalan Zhou; Junjie Lin; Renqing Zhao
Journal:  J Cardiovasc Transl Res       Date:  2022-08-29       Impact factor: 3.216

2.  Fibronectin type III domain-containing 5 in cardiovascular and metabolic diseases: a promising biomarker and therapeutic target.

Authors:  Xin Zhang; Can Hu; Hai-Ming Wu; Zhen-Guo Ma; Qi-Zhu Tang
Journal:  Acta Pharmacol Sin       Date:  2020-11-19       Impact factor: 7.169

3.  Association between irisin and metabolic parameters in nondiabetic, nonobese adults: a meta-analysis.

Authors:  Yan Li; Zhenbin Xu
Journal:  Diabetol Metab Syndr       Date:  2022-10-21       Impact factor: 5.395

Review 4.  Irisin and Incretin Hormones: Similarities, Differences, and Implications in Type 2 Diabetes and Obesity.

Authors:  Nicola Marrano; Giuseppina Biondi; Anna Borrelli; Angelo Cignarelli; Sebastio Perrini; Luigi Laviola; Francesco Giorgino; Annalisa Natalicchio
Journal:  Biomolecules       Date:  2021-02-15

Review 5.  The Emerging Role of Irisin in Cardiovascular Diseases.

Authors:  Jinjuan Fu; Fangtang Li; Yuanjuan Tang; Lin Cai; Chunyu Zeng; Yongjian Yang; Jian Yang
Journal:  J Am Heart Assoc       Date:  2021-10-08       Impact factor: 5.501

6.  Bilateral Paraventricular Nucleus Upregulation of Extracellular Superoxide Dismutase Decreases Blood Pressure by Regulation of the NLRP3 and Neurotransmitters in Salt-Induced Hypertensive Rats.

Authors:  Qing Su; Xiao-Jing Yu; Xiao-Min Wang; Hong-Bao Li; Ying Li; Juan Bai; Jie Qi; Nianping Zhang; Kai-Li Liu; Yan Zhang; Guo-Qing Zhu; Yu-Ming Kang
Journal:  Front Pharmacol       Date:  2021-11-25       Impact factor: 5.810

Review 7.  The Role of NRF2 in Obesity-Associated Cardiovascular Risk Factors.

Authors:  Jorge Gutiérrez-Cuevas; Marina Galicia-Moreno; Hugo Christian Monroy-Ramírez; Ana Sandoval-Rodriguez; Jesús García-Bañuelos; Arturo Santos; Juan Armendariz-Borunda
Journal:  Antioxidants (Basel)       Date:  2022-01-26

Review 8.  Effects of the FNDC5/Irisin on Elderly Dementia and Cognitive Impairment.

Authors:  Jin Peng; Jinhui Wu
Journal:  Front Aging Neurosci       Date:  2022-03-31       Impact factor: 5.750

Review 9.  Irisin, an Effective Treatment for Cardiovascular Diseases?

Authors:  Chen Liu; Aili Wei; Tianhui Wang
Journal:  J Cardiovasc Dev Dis       Date:  2022-09-13
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.